@Gussington did generalise: pre commercialisation, where revenue is less than expenses such as R&D and the like, is always going to be a slow increase in market cap relative to the share price.
Correction: ... is sometimes going to be a slow increase in market cap ...
And sometimes a complete duster, which becomes worthless.
I'm not a particularly insightful investor / stock-watcher, but I can only conclude that in Biotech especially, stocks with merit far outnumber stocks which reach success.
I'm holding a modest parcel, and I've buying in and selling out of this company for years. Not now or ever would I consider it a safe bet, of even avoiding a crash to 25% of current valuation.
Is it worth the risk ...?
Oh, yeah ... sort of. If you like risk.
I don't mind jumping in where fools fear to tread.
In other words, invest in it if you can afford to lose it.
Add to My Watchlist
What is My Watchlist?
